JP7781391B2 - 複素環式化合物及びその使用 - Google Patents

複素環式化合物及びその使用

Info

Publication number
JP7781391B2
JP7781391B2 JP2023565154A JP2023565154A JP7781391B2 JP 7781391 B2 JP7781391 B2 JP 7781391B2 JP 2023565154 A JP2023565154 A JP 2023565154A JP 2023565154 A JP2023565154 A JP 2023565154A JP 7781391 B2 JP7781391 B2 JP 7781391B2
Authority
JP
Japan
Prior art keywords
formula
optionally substituted
cancer
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023565154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514709A5 (https=
JP2024514709A (ja
Inventor
マーク エスポジト，
ジョン プラウドフット，
イービン カン，
ジョン ピウィンスキ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Original Assignee
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Princeton University filed Critical Princeton University
Publication of JP2024514709A publication Critical patent/JP2024514709A/ja
Publication of JP2024514709A5 publication Critical patent/JP2024514709A5/ja
Priority to JP2025196737A priority Critical patent/JP2026020230A/ja
Application granted granted Critical
Publication of JP7781391B2 publication Critical patent/JP7781391B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
JP2023565154A 2021-04-22 2022-04-22 複素環式化合物及びその使用 Active JP7781391B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025196737A JP2026020230A (ja) 2021-04-22 2025-11-17 複素環式化合物及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178309P 2021-04-22 2021-04-22
US63/178,309 2021-04-22
PCT/US2022/026059 WO2022226383A1 (en) 2021-04-22 2022-04-22 Heterocyclic compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025196737A Division JP2026020230A (ja) 2021-04-22 2025-11-17 複素環式化合物及びその使用

Publications (3)

Publication Number Publication Date
JP2024514709A JP2024514709A (ja) 2024-04-02
JP2024514709A5 JP2024514709A5 (https=) 2025-04-24
JP7781391B2 true JP7781391B2 (ja) 2025-12-08

Family

ID=83723210

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023565154A Active JP7781391B2 (ja) 2021-04-22 2022-04-22 複素環式化合物及びその使用
JP2025196737A Pending JP2026020230A (ja) 2021-04-22 2025-11-17 複素環式化合物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025196737A Pending JP2026020230A (ja) 2021-04-22 2025-11-17 複素環式化合物及びその使用

Country Status (11)

Country Link
US (2) US12054475B2 (https=)
EP (1) EP4326696A4 (https=)
JP (2) JP7781391B2 (https=)
KR (2) KR20260022493A (https=)
CN (1) CN117897370A (https=)
AU (1) AU2022262654A1 (https=)
CA (1) CA3213692A1 (https=)
IL (2) IL324964A (https=)
MX (1) MX2023012435A (https=)
WO (1) WO2022226383A1 (https=)
ZA (1) ZA202309153B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638881B (zh) 2018-07-31 2025-01-07 普林斯顿大学托管委员会 用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物
WO2021151062A1 (en) * 2020-01-24 2021-07-29 The Trustees Of Princeton Univeristy Heterocyclic compounds and uses thereof
IL324964A (en) 2021-04-22 2026-01-01 Kayothera Inc Modified heterocycles as aldehyde dehydrogenase inhibitors
CN116120316B (zh) * 2022-12-29 2025-12-05 渭南瑞联制药有限责任公司 一种氮杂三环抗菌化合物的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017522346A (ja) 2014-08-01 2017-08-10 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ ブロモドメインに対して活性な化合物
WO2020028461A1 (en) 2018-07-31 2020-02-06 The Trustees Of Princeton University Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60126270A (ja) 1983-12-14 1985-07-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
JPS61145162A (ja) 1984-12-19 1986-07-02 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
DE3701277A1 (de) * 1987-01-17 1988-07-28 Boehringer Mannheim Gmbh Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel
JPH01319453A (ja) 1988-06-22 1989-12-25 Wakamoto Pharmaceut Co Ltd 新規ベンゾキノン誘導体
ATE355273T1 (de) 2003-05-12 2006-03-15 Pfizer Prod Inc Benzamidinhibitoren des p2x7-rezeptors
US20050209247A1 (en) 2003-11-07 2005-09-22 Chiron Corporation Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
EP1718306A2 (en) 2004-02-20 2006-11-08 Chiron Corporation Modulation of inflammatory and metastatic processes
JPWO2006132295A1 (ja) 2005-06-09 2009-01-08 大日本住友製薬株式会社 アルドステロン受容体調節剤
JP2006349902A (ja) 2005-06-15 2006-12-28 Fujifilm Holdings Corp 黒白熱現像感光材料
WO2010102286A2 (en) 2009-03-06 2010-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Proteasome inhibitors having chymotrypsin-like activity
US8541404B2 (en) * 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
WO2013066469A2 (en) 2011-08-15 2013-05-10 Seattle Children's Research Institute Kinase inhibitors capable of increasing the sensitivity of bacterial pathogens to b-lactam antibiotics
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013170072A2 (en) * 2012-05-09 2013-11-14 Neurop, Inc. Compounds for the treatment of neurological disorders
CA2926250A1 (en) 2013-10-04 2015-04-09 Bayer Cropscience Aktiengesellschaft Use of substituted dihydro-oxindolyl sulfonamides, or the salts thereof, for increasing the stress tolerance of plants
WO2015092118A1 (en) 2013-12-17 2015-06-25 Orion Corporation Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
HUE051255T2 (hu) 2014-02-19 2021-03-01 Aviv Therapeutics Inc Mitokondriális aldehid dehidrogenáz 2 (ALDH2) kötõ policiklusos amidok és alkalmazásuk rák kezelésére
EP3143009B1 (en) 2014-05-12 2019-09-18 Fondazione Istituto Italiano di Tecnologia Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments
WO2018109650A1 (en) 2016-12-14 2018-06-21 Aurigene Discovery Technologies Limited Spiro[cyclopentane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
CN108690043B (zh) 2017-04-11 2019-10-18 东莞东阳光科研发有限公司 喹啉类衍生物及其制备方法和用途
WO2021151062A1 (en) 2020-01-24 2021-07-29 The Trustees Of Princeton Univeristy Heterocyclic compounds and uses thereof
GB202019475D0 (en) 2020-12-10 2021-01-27 Cancer Research Tech Ltd Therapeutic compounds and their use
IL324964A (en) 2021-04-22 2026-01-01 Kayothera Inc Modified heterocycles as aldehyde dehydrogenase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017522346A (ja) 2014-08-01 2017-08-10 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ ブロモドメインに対して活性な化合物
WO2020028461A1 (en) 2018-07-31 2020-02-06 The Trustees Of Princeton University Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers

Also Published As

Publication number Publication date
IL307873A (en) 2023-12-01
AU2022262654A1 (en) 2023-10-19
EP4326696A1 (en) 2024-02-28
MX2023012435A (es) 2024-02-08
KR20230173703A (ko) 2023-12-27
WO2022226383A1 (en) 2022-10-27
ZA202309153B (en) 2025-04-30
KR102925139B1 (ko) 2026-02-10
US20240132469A1 (en) 2024-04-25
JP2026020230A (ja) 2026-02-06
CN117897370A (zh) 2024-04-16
EP4326696A4 (en) 2025-06-25
IL307873B1 (en) 2026-01-01
JP2024514709A (ja) 2024-04-02
US20240343709A1 (en) 2024-10-17
IL324964A (en) 2026-01-01
US12054475B2 (en) 2024-08-06
CA3213692A1 (en) 2022-10-27
KR20260022493A (ko) 2026-02-19

Similar Documents

Publication Publication Date Title
JP7781391B2 (ja) 複素環式化合物及びその使用
US20240270736A1 (en) Macrocyclic heterocycles and uses thereof
KR20210098960A (ko) Helios의 소분자 분해제 및 사용 방법
CN109311839B (zh) 甲胺衍生物作为赖氨酰氧化酶抑制剂用于治疗癌症
CN104540828B (zh) 作为ii组代谢型谷氨酸受体的别构调节剂的取代的吡唑并喹唑啉酮和吡咯并喹唑啉酮
JP2026042873A (ja) 複素環式化合物およびその使用
CN115605475B (zh) 一种免疫抑制剂、其制备方法和应用
RU2552114C2 (ru) Конденсированные гетероарилы и их применение
RS54311B1 (sr) Kondezovani derivat aminodihidrotiazina
BR112020011746A2 (pt) compostos heterocíclicos bicíclicos substituídos atuando como inibidores de prmt5
JP2008519843A (ja) 特定のイミダゾ［１，２−ａ］ビラジン−８−イラミンズ、その生成方法及びそれに関する使用方法
KR20090074192A (ko) 치환된 아미드, 그의 제조 방법, 및 그의 사용 방법
BR112020000086A2 (pt) derivados de 2-(4-clorofenóxi)-n-((1-(2-(4-clorofenóxi) etinazetidin-3-il) metil) acetamida e compostos relacionados como inibidores de atf4 para tratamento de câncer e outras doenças
JP7357146B2 (ja) アザヘテロアリール化合物及びその使用
AU2019312393A1 (en) Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof
TW201821105A (zh) 使用ｈｄａｃ１１抑制劑之方法
KR20210134351A (ko) 통합 스트레스 반응 경로의 억제제
KR20140040104A (ko) 대사 및 염증 질병의 치료에 유용한 아제티딘 유도체
JP6970684B2 (ja) クマリン骨格を有するスルホンアミド誘導体
CN103923085B (zh) 具有刺猬通路拮抗剂活性的吡啶杂环化合物及其用途
JP2020511407A (ja) 併用療法
Li et al. Design, Synthesis, and Biological Evaluation of 3, 4-Dihydroisoquinolin-1 (2H)-one Derivatives as Protein Arginine Methyltransferase 5 Inhibitors for the Treatment of Non-Hodgkin’s Lymphoma
US20190152979A1 (en) Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group ii metabotropic glutamate receptors
CN114502556B (zh) 一种联苯基氟代双键衍生物及其制备方法和在药学上的应用
CN115246822B (zh) 嘧啶类化合物及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250416

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251016

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251117

R150 Certificate of patent or registration of utility model

Ref document number: 7781391

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150